Navigation Links
Pharmaceutical Budget and Staffing: Powerful New Metrics-Based Study
Date:2/7/2008

CHAPEL HILL, N.C., Feb. 7 /PRNewswire/ -- Falling stock prices, devaluing dollar, soaring gas prices, and the slumping real estate market are just a few of the symptoms of the recession hitting the U.S. economy. While a recession will impact all industries, it may have a deeper impact on pharma and biotech companies as they have already been dealing with increasing pricing and regulatory pressures and decreasing numbers of newly approved therapies. Given the current environment, it is imperative for companies to maintain the appropriate mix of budgets and staffing to meet corporate objectives.

The current report, U.S. Pharmaceutical Budget and Staffing Excellence: Benchmarking the Resources Required to Drive Productivity and Growth, can be an invaluable resource allowing pharmaceutical and biotech executives to critically assess key business functions and resources against thirty-six top pharma and biotech companies. The rich metrics contained in this comprehensive report emanate from survey responses from staffing executives at such elite pharmaceutical and biotech companies as Abbott Labs, AstraZeneca, Bristol-Myers Squibb, J&J, Eli Lilly GlaxoSmithKline, Merck, Novartis, Pfizer, Roche and Sanofi-Aventis.

Executive insight across seven critical functional areas, including:

* Marketing Operations

* Marketing Services

* Sales Support

* Managed Care

* State & Government Affairs

* Finance

* Legal and Compliance

Sampling of the key findings harnessed from the report include:

* Marketing Services groups support an average of 7.8 brands with 6.7 FTEs

allocated per brand promoted

* Sales Support groups allocate approximately $460,000, including labor,

overhead and outsourcing, per sales support FTE

* Managed Care groups report an average of 18 FTEs allocated to Customer

Marketing Strategy

* Finance budgets as a percentage of sales average 1.33%

* Legal and Compliance groups indicate an average spend of $199,702 per

FTE

To download a free excerpt of U.S. Pharmaceutical Budget and Staffing Excellence visit http://www3.best-in-class.com/rr827.htm. For more information, contact Cameron Tew at (919) 767-9246 or ctew@best-in-class.com.

BEST PRACTICES, LLC is a benchmarking and consulting firm that conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more information, call (919) 403-0251 or visit http://www.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
Breaking Biology Technology:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):